
Boehringer eyes H2 drug launches after strong H1 growth
Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025,
Newsletters and Deep Dive digital magazine
Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025,
Explore how athletes leverage data and DTC marketing, and learn how Big Pharma is borrowing from their successful playbook.
Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX
June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting appointments on the non-profit side.
HHS Secretary Robert F Kennedy Jr has formally signed off on a recommendation to remove thimerosal from all flu vaccines in the US
Editor's Picks
Newsletters and Deep Dive
digital magazine